CLDX - Celldex Therapeutics, Inc.
(NaN%)
Sell
Weak Growth●Earnings/Profit is Negative
24%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 1.55%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -1069.42%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 16.63
Debt Ratio is 0.1
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Celldex Therapeutics, Inc. (CLDX) - http://www.celldex.com
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.Exchange - NASDAQ
Industry - Medical Specialties
Sector - Health Technology
CEO - Anthony S. Marucci
Employees - 130
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.
Know the Stock © 2021 and future.